France's Sanofi completed the $11.6 billion acquisition of hemophilia drugmaker Bioverativ Inc.
The pharmaceuticals giant's tender offer to acquire all outstanding shares of Bioverativ for $105 apiece expired as scheduled on time.
Bioverativ will operate as a subsidiary of Sanofi and its common stock will cease to be traded on the Nasdaq.
